Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis

This study has been completed.
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) ) Identifier:
First received: July 18, 2012
Last updated: January 7, 2014
Last verified: January 2014

A study to evaluate the safety and efficacy of treatment in Chinese subjects with moderate to severe plaque psoriasis.

Condition Intervention Phase
Plaque Psoriasis
Biological: Adalimumab
Biological: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab (Humira®) in Chinese Subjects With Moderate to Severe Plaque Psoriasis

Resource links provided by NLM:

Further study details as provided by AbbVie:

Primary Outcome Measures:
  • Proportion of subjects achieving improvement in Psoriasis Area and Severity Index [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    Proportion of subjects achieving at least a 75% improvement in PASI at Week 12 relative to Baseline.

Secondary Outcome Measures:
  • Proportion of subjects achieving improvement in Psoriasis Area Severity Index [ Time Frame: Weeks 0 up to Week 24, excluding Week 12 ] [ Designated as safety issue: No ]
    Proportion of subjects achieving Psoriasis Area Severity Index 75 response at visits other than Week 12.

  • Change from baseline in Psoriasis Area Severity Index [ Time Frame: Weeks 0 up to Week 24 ] [ Designated as safety issue: No ]
    Subjects with a change in Psoriasis Area Severity Index since their Baseline visit.

  • Proportion of subjects achieving improvement in Physician Global Assessment [ Time Frame: Week 0 up to Week 24 ] [ Designated as safety issue: No ]
    Proportion of subject achieving a clear improvement in Physician Global Assessment

Enrollment: 425
Study Start Date: July 2012
Study Completion Date: December 2013
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: adalimumab every other week (eow)
adalimumab eow
Biological: Adalimumab
adalimumab eow
Other Name: ABT-D2E7, Humira
Placebo Comparator: Placebo
Biological: placebo

Detailed Description:

The purpose of this study is to evaluate the safety and efficacy of adalimumab and to determine how well it works in the treatment of adults with moderate to severe plaque psoriasis in the Chinese population. Psoriasis is a chronic immunologic disease characterized by marked inflammation and thickening of the epidermis that result in thick, scaly plaques involving the skin.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of psoriasis for at least 6 months.
  • Must have stable plaque psoriasis for at least 2 months before screening and baseline visits.
  • Subject must be willing to receive subcutaneous injections.
  • Subject must have a Psoriasis Area Severity Index score greater than or equal to 10 at the baseline visit.

Exclusion Criteria:

  • Diagnosis of other active skin diseases or skin infections.
  • Subject has known hypersensitivity to adalimumab or it excipients.
  • Subject has chronic recurring infections or active TB.
  • Subject has demyelinating disease (including myelitis) or neurologic symptoms suggestive of demyelinating disease.
  • Subject is known to have immune deficiency or is immunocompromised.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01646073

Site Reference ID/Investigator# 72873
Beijing, China, 100044
Site Reference ID/Investigator# 72887
Beijing, China, 100730
Site Reference ID/Investigator# 72888
Beijing, China, 100034
Site Reference ID/Investigator# 85693
Chengdu, China, 610072
Site Reference ID/Investigator# 72976
Chongqing, China, 400038
Site Reference ID/Investigator# 72880
Dalian, China, 116011
Site Reference ID/Investigator# 72973
Guangzhou, China, 510120
Site Reference ID/Investigator# 72974
Guangzhou, China, 510630
Site Reference ID/Investigator# 72877
Hangzhou, Zhejiang, China, 310009
Site Reference ID/Investigator# 72878
Hangzhou, Zhejiang, China, 310003
Site Reference ID/Investigator# 87058
Jinan, China, 250012
Site Reference ID/Investigator# 72875
Shanghai, China, 200433
Site Reference ID/Investigator# 72876
Shanghai, China, 200025
Site Reference ID/Investigator# 72883
Shenyang, China, 110001
Site Reference ID/Investigator# 72977
Wuhan, Hubei, China, 430022
Site Reference ID/Investigator# 72975
Xi'an, China, 710032
Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Study Chair: Martin Okun, MD AbbVie
  More Information

Additional Information:
No publications provided

Responsible Party: AbbVie ( AbbVie (prior sponsor, Abbott) ) Identifier: NCT01646073     History of Changes
Other Study ID Numbers: M13-606
Study First Received: July 18, 2012
Last Updated: January 7, 2014
Health Authority: China: Food and Drug Administration

Keywords provided by AbbVie:
Plaque Psoriasis
Placebo Controlled
Skin Disease
Double Blind

Additional relevant MeSH terms:
Skin Diseases
Skin Diseases, Papulosquamous
Anti-Inflammatory Agents
Antirheumatic Agents
Pharmacologic Actions
Therapeutic Uses processed this record on November 25, 2014